HOME >> BIOLOGY >> NEWS
Excellent survival rates for liver cancer patients undergoing transplant

More than 60 percent of liver transplant patients with advanced liver cancer are still alive after five years, compared to nearly zero survival for those patients who did not undergo transplant, according to a study by Johns Hopkins researchers.

"This is good news for patients with liver cancer. If diagnosed early, transplantation is the treatment of choice for patients with liver cancer and advanced cirrhosis," says Paul Thuluvath, M.D., associate professor of medicine at Johns Hopkins and lead author of the report published in the Dec. 1, issue of the Journal of Clinical Oncology and available online after Oct. 27.

Thuluvath emphasizes that regular screening of patients with cirrhosis, a risk factor for liver cancer, is needed to detect the cancer early and insure the best possible outcome.

In addition to the favorable five-year survival rates, Thuluvath and colleagues found that survival rates increased steadily over the last decade, suggesting that criteria for patient selection established by other experts may assist physicians in selecting those patients most likely to respond well to the procedure.

Using the United Network for Organ Sharing (UNOS) database, the researchers collected data on 48,887 patients who underwent liver transplantation in the United States between 1987 and 2001. Patients were excluded if they had undergone multiple organ transplantation or retransplantation, were less than 18 years of age, or lacked survival data.

Of the remaining patients included in the final analysis, 985 had liver transplantation for liver cancer and 33,339 patients had liver transplantation for other reasons (control group). Both the liver cancer and control groups were divided into three different five-year time periods: 1987 1991, 1992 1996, and 1997 2001.

Researchers found significant and steady improvement in survival over time among liver transplant patients with liver cancer, especially in the last f
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
30-Oct-2003


Page: 1 2

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Bad news for pathogenic bacteria: Scientists find protein essential for bacterial survival
3. Clue found on breast tumors distinguishes patients with better survival odds
4. Figs may inhibit growth and survival of harmful microbes in food
5. Study may improve survival of transplanted livers
6. Chromosome losses mean poor survival in childhood leukemia
7. Scientists identify six genes associated with survival in diffuse large B cell lymphoma
8. Predicting cancer patient survival with gene expression data
9. New approach limits damage after heart attack and improves survival, say Scripps Research scientists
10. Aggregation of cloned mouse embryos improves survival rate
11. UC Santa Barbara discovers cell survival gene may lead to treatments for degenerative diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology:
Cached News: